Stockscreener 앱 받기
1.87
4.10%
-0.08
시간 외 거래:
1.89
0.02
+1.07%
전일 마감가:
$1.95
열려 있는:
$1.97
하루 거래량:
580.89K
Relative Volume:
0.56
시가총액:
$202.58M
수익:
$27.08M
순이익/손실:
$-37.00M
주가수익비율:
-3.5962
EPS:
-0.52
순현금흐름:
$-18.46M
1주 성능:
+0.54%
1개월 성능:
-8.33%
6개월 성능:
+73.15%
1년 성능:
+61.21%
1일 변동 폭
$1.855
$1.97
1주일 범위
$1.84
$1.97
52주 변동 폭
$1.05
$5.17
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
명칭
Aclaris Therapeutics Inc
전화
484-324-7933
주소
701 LEE ROAD, WAYNE, PA
ACRS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
1.87 | 211.25M | 27.08M | -37.00M | -18.46M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-10 | 재개 | Piper Sandler | Overweight |
| 2025-05-28 | 개시 | Wedbush | Outperform |
| 2025-03-18 | 재개 | Cantor Fitzgerald | Overweight |
| 2024-12-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-11-20 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-19 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2024-11-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-11-19 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-11-18 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-01-22 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-11-13 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-10-03 | 개시 | Evercore ISI | Outperform |
| 2022-12-14 | 개시 | Stifel | Buy |
| 2022-12-01 | 개시 | Goldman | Buy |
| 2022-10-06 | 개시 | BTIG Research | Buy |
| 2021-07-23 | 재개 | Jefferies | Buy |
| 2021-06-15 | 개시 | Piper Sandler | Overweight |
| 2021-04-21 | 개시 | H.C. Wainwright | Buy |
| 2019-10-22 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-06 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-27 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-05-06 | 개시 | SVB Leerink | Outperform |
| 2018-03-28 | 재개 | Leerink Partners | Outperform |
| 2018-02-09 | 개시 | Guggenheim | Buy |
| 2017-06-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-11-29 | 개시 | Leerink Partners | Outperform |
| 2016-09-30 | 개시 | JMP Securities | Mkt Outperform |
| 2016-06-10 | 개시 | Guggenheim | Buy |
| 2015-11-02 | 개시 | Citigroup | Buy |
| 2015-11-02 | 개시 | Jefferies | Buy |
모두보기
Aclaris Therapeutics Inc 주식(ACRS)의 최신 뉴스
Full technical analysis of Aclaris Therapeutics Inc. stock2025 Investor Takeaways & Real-Time Sentiment Analysis - newser.com
Real time alert setup for Aclaris Therapeutics Inc. performanceQuarterly Portfolio Review & Fast Exit and Entry Trade Guides - newser.com
Real time breakdown of Aclaris Therapeutics Inc. stock performanceJuly 2025 Technicals & Fast Exit and Entry Trade Guides - newser.com
Building trade automation scripts for Aclaris Therapeutics Inc.Portfolio Update Summary & Stepwise Entry and Exit Trade Signals - newser.com
Is Aclaris Therapeutics Inc. (8AT) stock testing key supportGDP Growth & Stock Portfolio Risk Control - newser.com
Atopic Dermatitis Pipeline Outlook Report 2025: Insight into emerging drugs, treatment options, clinical trials, and company strategies - The Globe and Mail
What analysts say about Aclaris Therapeutics Inc 8AT stockMarket Sentiment Shifts & Outperform the Market with Aggressive Picks - earlytimes.in
How Aclaris Therapeutics Inc. stock performs during Fed tightening cyclesEarnings Recap Report & Weekly Top Gainers Alerts - newser.com
Sentiment analysis tools applied to Aclaris Therapeutics Inc.July 2025 Catalysts & Risk Adjusted Buy/Sell Alerts - newser.com
Will Aclaris Therapeutics Inc. rebound enough to break evenRate Cut & High Accuracy Trade Signal Alerts - newser.com
Risk vs reward if holding onto Aclaris Therapeutics Inc.July 2025 Earnings & Reliable Volume Spike Alerts - newser.com
Real time scanner hits for Aclaris Therapeutics Inc. explainedCEO Change & Daily Stock Trend Reports - newser.com
Will Aclaris Therapeutics Inc. (8AT) stock profit from automation waveGold Moves & High Yield Equity Trading Tips - newser.com
Using fundamentals and technicals on Aclaris Therapeutics Inc.Weekly Market Report & High Yield Stock Recommendations - newser.com
Aclaris to Host 2025 R&D Day in New York to Spotlight Immuno-Inflammatory Pipeline - MyChesCo
Using Bollinger Bands to evaluate Aclaris Therapeutics Inc.July 2025 PostEarnings & High Yield Stock Recommendations - newser.com
How high can Aclaris Therapeutics Inc. stock goCPI Data & Free Community Supported Trade Ideas - newser.com
Will Aclaris Therapeutics Inc. (8AT) stock beat revenue estimatesWeekly Trade Review & Accurate Intraday Trade Tips - newser.com
Published on: 2025-10-02 23:56:18 - newser.com
What drives Aclaris Therapeutics Inc stock priceBreakout Stock Watch & Exceptional Return Investment - earlytimes.in
Does Aclaris Therapeutics Inc. qualify in momentum factor screeningWeekly Risk Summary & Precise Buy Zone Tips - newser.com
Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025 - Sahm
Aclaris Therapeutics to Host In-Person and Webcast R&D Day, "Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets", in New York on October 14, 2025 - Investing News Network
Aclaris Therapeutics to Host In-Person and Webcast R&D Day, 'Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025 - The Manila Times
Aclaris Therapeutics to Host In-Person and Webcast R&D Day, - GlobeNewswire
How to read the order book for Aclaris Therapeutics Inc.2025 Sector Review & Community Consensus Trade Alerts - newser.com
Wayne’s Aclaris Therapeutics Signs Exclusive Licensing Deal with Chinese Biotech - MSN
Published on: 2025-09-29 10:26:08 - newser.com
Aclaris Therapeutics Inc (ACRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Aclaris Therapeutics Inc 주식 (ACRS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Mehra Anand | Director |
Nov 19 '24 |
Buy |
2.25 |
666,666 |
1,499,998 |
710,030 |
5.74%
자본화:
|
볼륨(24시간):